Sample characteristics for those included at baseline with valid MRIs, age, intelligence quotient, reported handedness, ADHD symptom severity, and brain ROIs, as well as scan movement ratings at baseline and follow-up and scan interval and compliance rates for those included in the analyses, divided by age and medication groupa
Children |
Adults |
|||||||
---|---|---|---|---|---|---|---|---|
Methylphenidate Hydrochloride (n = 25) |
Placebo (n = 23) |
Methylphenidate Hydrochloride (n = 24) |
Placebo (n = 23) |
|||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
Age at baseline (yr) | 11.4 | 0.8 | 11.4 | 0.9 | 28.2 | 4.4 | 29.0 | 5.0 |
Estimated intelligence quotientb | 104.8 | 21.0 | 102.8 | 15.7 | 107.9 | 8.8 | 107.9 | 6.4 |
ADHD symptom severity | 36.6 | 6.2 | 38.4 | 8.2 | 31.8 | 9.9 | 31.0 | 9.9 |
Proportion right-handed | 0.840 | 0.374 | 0.913 | 0.288 | 0.958 | 0.204 | 0.826 | 0.388 |
Left frontal cortex thickness, Tp1 (mm)c | 2.805 | 0.229 | 2.763 | 0.236 | 2.471 | 0.170 | 2.553 | 0.164 |
Right medial cortex thickness, Tp1 (mm)c | 2.724 | 0.115 | 2.770 | 0.097 | 2.434 | 0.128 | 2.438 | 0.120 |
Right posterior cortex thickness, Tp1 (mm)c | 2.409 | 0.142 | 2.384 | 0.172 | 2.151 | 0.157 | 2.223 | 0.096 |
Scan movement Tp1c | 1.2 | 0.4 | 1.2 | 0.4 | 1.0 | 0.0 | 1.1 | 0.2 |
Scan movement Tp2d | 1.3 | 0.5 | 1.2 | 0.4 | 1.1 | 0.2 | 1.0 | 0.0 |
Compliance rate percentagee | 83.5 | 15.5 | 79.0 | 18.1 | 90.0 | 8.0 | 85.7 | 8.4 |
Scan interval (day)f | 122.3 | 4.2 | 121.4 | 3.9 | 110.8 | 27.5 | 111.7 | 24.6 |
Note:—Tp indicates time point; Tp1, baseline time point; and Tp2, follow-up time point.
There were no significant (P < .05) differences in these characteristics across participants randomized to methylphenidate or placebo treatment.
Available for 21 children and 22 adults in the placebo group and all 25 children and 22 adults in the methylphenidate group.
Available for those with scans included at baseline: 23 children and 22 adults in the placebo group and 24 children and 24 adults in methylphenidate group.
Available for those with scans included at follow-up: 23 children and 21 adults in placebo group and 22 children and 22 adults in methylphenidate group.
Available for 22 children and 21 adults in the placebo group and 20 children and 22 adults in the methylphenidate group.
Available for those included who did not drop out: 23 children and 21 adults in placebo group and 23 children and 22 adults in methylphenidate group.